NovaBridge Biosciences
NBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $2 | $23 |
| - Cash | $0 | $2 | $3 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$1 | -$1 | $19 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | -100% | 141.9% | -112.2% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | 100% | 2,325.8% | 47.3% |
| EBITDA | -$0 | -$0 | -$0 | -$2 |
| % Margin | – | -7,674.2% | 478.9% | -2,337.4% |
| Net Income | -$0 | -$1 | -$3 | -$2 |
| % Margin | – | -32,674% | 23,438.9% | -2,648.7% |
| EPS Diluted | -4.46 | -17.62 | -30.38 | -30.68 |
| % Growth | 74.7% | 42% | 1% | – |
| Operating Cash Flow | -$0 | -$0 | -$1 | -$1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$1 | -$1 |